CN

Faculty

Home  >  Faculty  >  Content


Biography

A central focus   of Dr. Wang’s work has been the study of viral surface proteins, including   the Env protein of HIV-1 and the Spike protein of coronaviruses—molecules   that play a critical role in viral entry and immune recognition. Her research   in this area has provided valuable insights into the mechanisms by which   viruses escape immune pressure, laying the groundwork for the development of   more effective neutralizing antibodies, vaccines and therapeutic strategies.


Dr. Wang has published more than 40 research papers in leading scientific journals, including Nature, Cell, The New England Journal of Medicine, The Lancet, Cell Host & Microbe, The Lancet Infectious Diseases, and Cell Reports, and so on.

Research

Dr. Wang Qian has long dedicated herself to the study of viral evolution, viral infection, and the human humoral immune response. Looking ahead, her research will center on uncovering the molecular foundations of viral mutation and transmission, exploring how immune pressure shapes antigenic variation, forecasting evolutionary trajectories of viruses, and enhancing surveillance of population-level immunity. Through this work, she seeks to illuminate the connections between virus evolution and the risks it poses to public health.

Representative  Publications

1. Wang Q*, Guo Y*, Casner RG*, Yu J, Nair MS, Ho J, Reddem ER, Tzang   CC, Huang Y, Shapiro L, Liu L. Optimizing a Human Monoclonal Antibody for   Better Neutralization of SARS-CoV-2. Nature Communications 2025.   Accepted in principle.

2. Wang Q*, Guo Y*, Ho J, Ho DD. Activity of Research-Grade   Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages. New   England Journal of Medicine 2024   Nov 14;391(19):1863-1864.

3. Wang Q*, Guo Y*, Mellis IA*, Wu M*, Mohri H, Gherasim C, Valdez R, Purpura LJ, Yin MT, Gordon A, Ho DD.   Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC. Cell   Reports. 2025 Apr 8;44(4):115543.   doi: 10.1016/j.celrep.2025.115543.

4. Wang Q*,   Mellis IA*, Wu M*, Bowen A*, Gherasim C, Valdez R, Shah JG, Purpura LJ, Yin   MT, Gordon A, Guo Y, Ho DD. KP.2-based monovalent mRNA vaccines robustly   boost antibody responses to SARS-CoV-2. The Lancet Infectious   Diseases 2025 Feb   4:S1473-3099(25)00058-1.

5. Wang Q*,   Mellis IA*, Ho J*, Bowen A, Kowalski-Dobson T, Valdez R, Katsamba PS, Wu M,   Lee C, Shapiro L, Gordon A, Guo Y, Ho DD, Liu L. Recurrent SARS-CoV-2 spike   mutations confer growth advantages to select JN.1 sublineages. Emerging Microbes   & Infections 2024 Sep   11:2402880.

6. Wang Q*, Mellis   IA*, Guo Y*, Gherasim C, Valdez R, Gordon A, Ho DD, Liu L. Robust   SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5   mRNA vaccine booster. Cell Reports Medicine 2024 Aug 23:101701.  

7. Wang Q*, Guo   Y*, Bowen A*, Mellis IA*, Valdez R, Gherasim C, Gordon A, Liu L, Ho DD.   XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing   antibodies against emerging SARS-CoV-2 variants. Cell Host &   Microbe 2024 Mar 13;32(3):315-321.e3.

8. Wang Q*, Guo   Y*, Schwanz LT*, Mellis IA*, Sun Y, Qu Y, Urtecho G, Valdez R, Stoneman E,   Gordon A, Wang HH, Ho DD, Liu L. SARS-CoV-2 omicron BA.2.87.1 exhibits higher   susceptibility to serum neutralization than EG.5.1 and JN.1. Emerging Microbes   & Infections 2024 Dec;13(1):2359004.

9. Wang Q,   Zhang S, Nguyen HT, Sodroski JG. Inhibition of human immunodeficiency virus   (HIV-1) infectivity by expression of poorly or broadly neutralizing   antibodies against Env in virus-producing cells. Journal of Virology 2024   Feb 20;98(2):e0159423.

10. Wang Q*, Guo   Y*, Liu L*, Schwanz LT, Li Z, Nair MS, Ho J, Zhang RM, Iketani S, Yu J, Huang   Y, Qu Y, Valdez R, Lauring AS, Huang Y, Gordon A, Wang HH, Liu L, Ho DD.   Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature   2023 Dec;624(7992):639-644.

11. Wang Q*, Guo   Y*, Tam AR*, Valdez R, Gordon A, Liu L, Ho DD. Deep immunological imprinting   due to the ancestral spike in the current bivalent COVID-19 vaccine. Cell   Reports Medicine 2023 Nov 21;4(11):101258.

12. Wang Q*, Bowen A*, Ho J*,   Zhang RM*, Valdez R, Stoneman E, Gordon A, Liu L, Ho DD. SARS-CoV-2   neutralising antibodies after a second BA.5 bivalent booster. Lancet   2023 Nov 18;402(10415):1827-1828.

13. Wang Q*, Guo Y*, Zhang RM*,   Ho J*, Mohri H, Valdez R, Manthei DM, Gordon A, Liu L, Ho DD. Antibody   neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6. The   Lancet Infectious Diseases 2023 Oct;23(10):e397-e398.

14. Wang Q*, Li Z*, Guo   Y*, Mellis IA*, Iketani S, Liu M, Yu J, Valdez R, Lauring AS, Sheng Z, Gordon   A, Liu L, Ho DD. Evolving antibody evasion and receptor affinity of the   Omicron BA.2.75 sublineage of SARS-CoV-2. iScience 2023   Oct 18;26(11):108254.

15. Liu L*,   Casner RA*,   Guo Y*, Wang   Q*,   Iketani S*,   Chan JFW*, Yu J, Dadonaite B, Nair MS, Mohri H,   Reddem ER, Yuan S, Poon VK, Chan CC, Yuen KY, Sheng Z, Huang Y, Bloom JD,   Shapiro L, Ho DD. Antibodies targeting a quaternary site on SARS-CoV-2 spike   glycoprotein prevent viral receptor engagement by conformational locking. Immunity   2023 Oct 10;56(10):2442-2455.e8.


Address ：115 Donghu Road, Wuchang District, Wuhan, Hubei Province

E-mail ：office.tkms@whu.edu.cn

© Taikang Center for Life and Medical Sciences of Wuhan University